Gravitate Health FHIR Implementation Guide
0.1.0 - CI Build

Gravitate Health FHIR Implementation Guide, published by Gravitate Health Project. This guide is not an authorized publication; it is the continuous build for version 0.1.0 built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/joofio/test-epi-composition/ and changes regularly. See the Directory of published versions

Example Bundle: ePI document Bundle for tovanor Package Leaflet for language en

Composition category:



Full name:


Authorised dose form:

Legal status of supply:

Domain:

Resource status:


Product classification:

Document Details

Generated Narrative: Bundle TEST PURPOSES ONLY - tovanor


Document Subject

Generated Narrative: MedicinalProductDefinition mp2be054305b85e2d13e65aa3cf1a561c0

identifier: http://ema.europa.eu/identifier/EU/1/12/790/001-008

type: Medicinal Product

domain: Human use

status: active

legalStatusOfSupply: Medicinal product subject to medical prescription

name

productName: Tovanor Breezhaler 44 micrograms inhalation powder, hard capsules

type: Full name

part

part: nan

type: Invented name part

part

part: nan

type: Scientific name part

part

part: nan

type: Strength part

part

part: nan

type: Pharmaceutical dose form part

Usages

-CountryJurisdictionLanguage
*EUEUen

Document Content

Generated Narrative: Composition composition-en-2be054305b85e2d13e65aa3cf1a561c0

Language: en

Profile: Composition (ePI)

identifier: http://ema.europa.eu/identifier/EU/1/12/790/001-008

status: Final

type: Package Leaflet

category: Raw

date: 2022-02-16 13:28:17+0000

author: Organization ACME industry

title: TEST PURPOSES ONLY - tovanor

Attesters

-ModeTime
*Official2022-02-16 13:28:17+0000

B. Package Leaflet

unavailable

Package leaflet: Information for the user

What is in this leaflet

What is in this leaflet

  1. What Tovanor Breezhaler is and what it is used for
  2. What you need to know before you use Tovanor Breezhaler
  3. How to use Tovanor Breezhaler
  4. Possible side effects
  5. How to store Tovanor Breezhaler
  6. Contents of the pack and other information

1. What tovanor is and what it is used for

What Tovanor Breezhaler is This medicine contains an active substance called glycopyrronium bromide. This belongs to a group of medicines called bronchodilators.

What Tovanor Breezhaler is used for This medicine is used to make breathing easier for adult patients who have breathing difficulties due to a lung disease called chronic obstructive pulmonary disease (COPD).

In COPD the muscles around the airways tighten. This makes breathing difficult. This medicine blocks the tightening of these muscles in the lungs, making it easier for air to get in and out of the lungs.

If you use this medicine once a day, it will help to reduce the effects of COPD on your everyday life.

2. What you need to know before you take tovanor

Do not use Tovanor Breezhaler

  • if you are allergic to glycopyrronium bromide or any of the other ingredients of this medicine (listed in section 6).

Warnings and precautions Talk to your doctor before using Tovanor Breezhaler, if any of the following applies to you:

  • you have kidney problems.
  • you have an eye problem called narrow-angle glaucoma.
  • you have difficulty passing urine.

During treatment with Tovanor Breezhaler, stop taking this medicine and tell your doctor immediately:

  • if you experience tightness of the chest, coughing, wheezing or breathlessness immediately after using Tovanor Breezhaler (signs of bronchospasm).
  • if you experience difficulties in breathing or swallowing, swelling of the tongue, lips or face, skin rash, itching and hives (signs of allergic reaction).
  • if you experience eye pain or discomfort, temporary blurring of vision, visual halos or coloured images in association with red eyes. These may be signs of an acute attack of narrow-angle glaucoma.

Tovanor Breezhaler is used as a maintenance treatment for your COPD. Do not use this medicine to treat a sudden attack of breathlessness or wheezing.

Children and adolescents Do not give this medicine to children or adolescents below the age of 18 years.

Other medicines and Tovanor Breezhaler Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines. This includes medicines similar to Tovanor Breezhaler used for your lung disease, such as ipratropium, oxitropium or tiotropium (so called anticholinergics).

No specific side effects have been reported when Tovanor Breezhaler has been used together with other medicines used to treat COPD such as reliever inhalers (e.g. salbutamol), methylxanthines (e.g. theophylline) and/or oral and inhaled steroids (e.g. prednisolone).

Pregnancy, breast-feeding and fertility If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine.

There are no data from the use of this medicine in pregnant women and it is not known whether the active substance of this medicine passes into human milk.

Driving and using machines It is unlikely that this medicine will affect your ability to drive and use machines.

Tovanor Breezhaler contains lactose This medicine contains lactose. If you have been told by your doctor that you have an intolerance to some sugars, contact your doctor before taking this medicine.

3. How to take tovanor

Always use this medicine exactly as your doctor or pharmacist has told you. Check with your doctor or pharmacist if you are not sure.

How much Tovanor Breezhaler to use The usual dose is to inhale the content of one capsule each day. You only need to inhale once a day because the effect of this medicine lasts for 24 hours. Do not use more than your doctor tells you to use.

Elderly people You can use this medicine if you are aged 75 years and over at the same dose as for other adults.

When to inhale Tovanor Breezhaler Use this medicine at the same time each day. This will also help you to remember to use it.

You can inhale this medicine anytime before or after food or drink. How to inhale Tovanor Breezhaler

  • In this pack, you will find an inhaler and capsules (in blisters) that contain the medicine as inhalation powder. Only use the capsules with the inhaler provided in this pack (Tovanor Breezhaler inhaler). The capsules should remain in the blister until you need to use them.
  • Do not push the capsule through the foil.
  • When you start a new pack, use the new Tovanor Breezhaler inhaler that is supplied in the pack.
  • Dispose of each inhaler after after all capsules in that pack have been used.
  • Do not swallow the capsules.
  • Please read the instructions at the end of this leaflet for more information on how to use the inhaler.

If you use more Tovanor Breezhaler than you should If you have inhaled too much of this medicine or if someone else accidentally uses your capsules, you must immediately either tell your doctor or go to the nearest emergency unit. Show the pack of Tovanor Breezhaler. Medical attention may be needed.

If you forget to use Tovanor Breezhaler If you forget to inhale a dose, take one as soon as possible. However, do not take two doses on the same day. Then take the next dose as usual.

How long to continue your treatment with Tovanor Breezhaler

  • Keep using this medicine for as long as your doctor tells you.
  • COPD is a long-term disease and you should use this medicine every day and not only when you have breathing problems or other symptoms of COPD. If you have questions about how long to continue your treatment with this medicine, talk to your doctor or pharmacist.

If you have any further questions on the use of this medicine, ask your doctor, pharmacist or nurse.

4. Possible side effects

Like all medicines, this medicine can cause side effects, although not everybody gets them.

Some side effects may be serious but are uncommon (may affect up to 1 in 100 people)

Irregular heart beat

High level of blood sugar (hyperglycaemia: typical symptoms include excessive thirst or hunger and frequent urination)

Rash, itching, hives, difficulty breathing or swallowing, dizziness (possible signs of allergic reaction)

Swelling mainly of the tongue, lips, face or throat (possible signs of angioedema) If you get any of these side effects, tell your doctor immediately.

Some side effects may be serious, but the frequency of these side effects is not known (frequency cannot be estimated from the available data)

Difficulty breathing with wheezing or coughing (signs of paradoxical bronchospasm)

Some side effects are common (may affect up to 1 in 10 people)

Dry mouth

Difficulty sleeping

Runny or stuffy nose, sneezing, sore throat

Diarrhoea or stomach ache

Musculoskeletal pain Some side effects are uncommon (may affect up to 1 in 100 people)

Difficulty and pain when passing urine

Painful and frequent urination

Palpitations

Rash

Numbness

Cough with sputum

Dental caries

Feeling of pressure or pain in the cheeks and forehead

Nose bleeds

Pain in arms or legs

Pain in muscles, bones or joints of the chest

Stomach discomfort after meals

Throat irritation

Tiredness

Weakness

Itching

Voice alteration (hoarseness)

Nausea

Vomiting

Some elderly patients above 75 years of age experienced headache (frequency common) and urinary tract infection (frequency common).

Reporting of side effects If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the national reporting system listed in Appendix V. By reporting side effects you can help provide more information on the safety of this medicine.

5. How to store tovanor

Keep this medicine out of the sight and reach of children.

Do not use this medicine after the expiry date which is stated on the carton and blister after EXP . The expiry date refers to the last day of that month.

Do not store above 25 C.

Store the capsules in the original blister in order to protect from moisture. Do not remove from the blister until immediately before use.

The inhaler in each pack should be disposed of after all capsules in that pack have been used.

Do not use this medicine if you notice that the pack is damaged or shows signs of tampering.

Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.

6. Contents of the pack and other information

What Tovanor Breezhaler contains

  • The active substance is glycopyrronium bromide. Each capsule contains 63 micrograms of glycopyrronium bromide (equivalent to 50 micrograms glycopyrronium). The delivered dose (the dose that leaves the mouthpiece of the inhaler) is equivalent to 44 micrograms of glycopyrronium.
  • The other ingredients of the inhalation powder are lactose monohydrate and magnesium stearate.

What Tovanor Breezhaler looks like and contents of the pack Tovanor Breezhaler 44 micrograms inhalation powder, hard capsules are transparent and orange and contain a white powder. They have the product code GPL50 printed in black above and a company logo ( ) printed in black below a black bar.

Each pack contains a device called an inhaler, together with capsules in blisters. Each blister strip contains either 6 or 10 hard capsules.

The following pack sizes are available: Packs containing 6x1, 10x1, 12x1 or 30x1 hard capsules, together with one inhaler.

Multipacks containing 90 (3 packs of 30x1) hard capsules and 3 inhalers. Multipacks containing 96 (4 packs of 24x1) hard capsules and 4 inhalers. Multipacks containing 150 (15 packs of 10x1) hard capsules and 15 inhalers. Multipacks containing 150 (25 packs of 6x1) hard capsules and 25 inhalers.

Not all pack sizes may be available in your country.

Marketing Authorisation Holder Novartis Europharm Limited Vista Building Elm Park, Merrion Road Dublin 4 Ireland

Manufacturer Novartis Farmac utica SA Gran Via de les Corts Catalanes, 08013 Barcelona Spain

Novartis Pharma GmbH Roonstra e D-90429 Nuremberg Germany

For any information about this medicine, please contact the local representative of the Marketing Authorisation Holder:

Belgi /Belgique/Belgien Novartis Pharma N.V. T l/Tel: +32 2 246 16 Lietuva SIA Novartis Baltics Lietuvos filialas Tel: +370 5 269 16
Novartis Bulgaria EOOD .: +359 2 489 98 Luxembourg/Luxemburg Novartis Pharma N.V. T l/Tel: +32 2 246 16 esk republika Novartis s.r.o. Tel: +420 225 775 Magyarorsz g Novartis Hung ria Kft. Tel.: +36 1 457 65 Danmark Novartis Healthcare A/S Tlf: +45 39 16 84 Malta Novartis Pharma Services Inc. Tel: +356 2122 2Deutschland Novartis Pharma GmbH Tel: +49 911 273 0

Nederland Novartis Pharma B.V. Tel: +31 88 04 52 Eesti SIA Novartis Baltics Eesti filiaal Tel: +372 66 30 Norge Novartis Norge AS Tlf: +47 23 05 20
Novartis (Hellas) A.E.B.E. : +30 210 28 11
INNOVIS PHARMA
: +30 210 66 64 805-6

sterreich Novartis Pharma GmbH Tel: +43 1 86 6Espa a Laboratorios Gebro Pharma, S.A. Tel: +34 93 205 86 Polska Novartis Poland Sp. z o.o. Tel.: +48 22 375 4France Novartis Pharma S.A.S. T l: +33 1 55 47 66 Portugal Laborat rio Medinfar - Produtos Farmac uticos, S.A. Tel: +351 21 499 7Hrvatska Novartis Hrvatska d.o.o. Tel. +385 1 6274 Rom nia Novartis Pharma Services Romania SRL Tel: +40 21 31299 Ireland Novartis Ireland Limited Tel: +353 1 260 12 Slovenija Novartis Pharma Services Inc. Tel: +386 1 300 75 sland Vistor hf. S mi: +354 535 7Slovensk republika Novartis Slovakia s.r.o. Tel: +421 2 5542 5Italia Alfasigma S.p.A. Tel: +39 06 91 39 4Suomi/Finland Novartis Finland Oy Puh/Tel: +358 (0)10 6133
Novartis Pharma Services Inc. : +357 22 690 Sverige Novartis Sverige AB Tel: +46 8 732 32 Latvija SIA Novartis Baltics Tel: +371 67 887 United Kingdom (Northern Ireland) Novartis Ireland Limited Tel: +44 1276 698This leaflet was last revised in

Other sources of information Detailed information on this medicine is available on the European Medicines Agency website: http://www.ema.europa.eu Instructions for use of Tovanor Breezhaler inhaler

Please read the full Instructions for Use before using the Tovanor Breezhaler.

Insert Pierce and release Inhale deeply Check capsule is empty

Step 1a: Pull off cap Step 2a: Pierce capsule once Hold the inhaler upright. Pierce capsule by firmly pressing both side buttons at the same time. Step 3a: Breathe out fully Do not blow into the inhaler. Check capsule is empty Open the inhaler to see if any powder is left in the capsule.

You should hear a noise as the capsule is pierced. Only pierce the capsule once.

If there is powder left in the capsule:

Close the inhaler.

Repeat steps 3a to 3c. Step 1b: Open inhaler

Step 2b: Release side buttons Step 3b: Inhale medicine deeply Hold the inhaler as shown in the picture. Place the mouthpiece in your mouth and close your lips firmly around it. Do not press the side buttons.

Powder Empty remaining 1

2

3

Check

Breathe in quickly and as deeply as you can. During inhalation you will hear a whirring noise. You may taste the medicine as you inhale.

Step 1c: Remove capsule Separate one of the blisters from the blister card. Peel open the blister and remove the capsule. Do not push the capsule through the foil. Do not swallow the capsule.

Step 3c: Hold breath Hold your breath for up to 5 seconds. Remove empty capsule Put the empty capsule in your household waste. Close the inhaler and replace the cap.

Step 1d: Insert capsule Never place a capsule directly into the mouthpiece.

Important Information Tovanor Breezhaler capsules must always be stored in the blister card and only removed immediately before use. Do not push the capsule through the foil to remove it from the blister. Do not swallow the capsule. Do not use the Tovanor Breezhaler capsules with any other inhaler. Do not use the Tovanor Breezhaler inhaler to take any other capsule medicine. Never place the capsule into your mouth or the mouthpiece of the inhaler. Do not press the side buttons more than once. Do not blow into the mouthpiece. Do not press the side buttons while inhaling through the mouthpiece. Do not handle capsules with wet hands. Never wash your inhaler with water.

Step 1e: Close inhaler

Your Seebri Breezhaler Inhaler pack contains: One Seebri Breezhaler inhaler One or more blister cards, each containing either 6 or 10 Seebri Breezhaler capsules to be used in the inhaler

Frequently Asked Questions

Why didn t the inhaler make a noise when I inhaled? The capsule may be stuck in the capsule chamber. If this happens, carefully loosen the capsule by tapping the base of the inhaler. Inhale the medicine again by repeating steps 3a to 3c.

What should I do if there is powder left inside the capsule? You have not received enough of your medicine. Close the inhaler and repeat steps 3a to 3c.

I coughed after inhaling does this matter? This may happen. As long as the capsule is empty you have received enough of your medicine.

I felt small pieces of the capsule on my tongue
does this matter? This can happen. It is not harmful. The chances of the capsule breaking into small pieces will be increased if the capsule is pierced more than once. Cleaning the inhaler Wipe the mouthpiece inside and outside with a clean, dry, lint-free cloth to remove any powder residue. Keep the inhaler dry. Never wash your inhaler with water. Disposing of the inhaler after use Each inhaler should be disposed of after all capsules have been used. Ask your pharmacist how to dispose of medicines and inhalers that are no longer required.

Blister Card Blister Inhaler base Inhaler Base Cap Side buttons Capsule chamber Mouthpiece Screen


Additional Resources Included in Document


Entry 1 - fullUrl = Composition/composition-en-2be054305b85e2d13e65aa3cf1a561c0

Resource Composition:

Generated Narrative: Composition composition-en-2be054305b85e2d13e65aa3cf1a561c0

Language: en

Profile: Composition (ePI)

identifier: http://ema.europa.eu/identifier/EU/1/12/790/001-008

status: Final

type: Package Leaflet

category: Raw

date: 2022-02-16 13:28:17+0000

author: Organization ACME industry

title: TEST PURPOSES ONLY - tovanor

Attesters

-ModeTime
*Official2022-02-16 13:28:17+0000

Entry 2 - fullUrl = MedicinalProductDefinition/mp2be054305b85e2d13e65aa3cf1a561c0

Resource MedicinalProductDefinition:

Generated Narrative: MedicinalProductDefinition mp2be054305b85e2d13e65aa3cf1a561c0

identifier: http://ema.europa.eu/identifier/EU/1/12/790/001-008

type: Medicinal Product

domain: Human use

status: active

legalStatusOfSupply: Medicinal product subject to medical prescription

name

productName: Tovanor Breezhaler 44 micrograms inhalation powder, hard capsules

type: Full name

part

part: nan

type: Invented name part

part

part: nan

type: Scientific name part

part

part: nan

type: Strength part

part

part: nan

type: Pharmaceutical dose form part

Usages

-CountryJurisdictionLanguage
*EUEUen